CY1119425T1 - Ενωσεις φαινοξυαιθυλο πιπεριδινης - Google Patents
Ενωσεις φαινοξυαιθυλο πιπεριδινηςInfo
- Publication number
- CY1119425T1 CY1119425T1 CY20171100979T CY171100979T CY1119425T1 CY 1119425 T1 CY1119425 T1 CY 1119425T1 CY 20171100979 T CY20171100979 T CY 20171100979T CY 171100979 T CY171100979 T CY 171100979T CY 1119425 T1 CY1119425 T1 CY 1119425T1
- Authority
- CY
- Cyprus
- Prior art keywords
- peperidines
- faoxythyline
- units
- methyl
- formula
- Prior art date
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665951P | 2012-06-29 | 2012-06-29 | |
| US201361779099P | 2013-03-13 | 2013-03-13 | |
| PCT/US2013/046684 WO2014004229A1 (en) | 2012-06-29 | 2013-06-20 | Phenoxyethyl piperidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119425T1 true CY1119425T1 (el) | 2018-03-07 |
Family
ID=48746666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100979T CY1119425T1 (el) | 2012-06-29 | 2017-09-15 | Ενωσεις φαινοξυαιθυλο πιπεριδινης |
Country Status (42)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| KR101807981B1 (ko) | 2013-12-17 | 2017-12-11 | 일라이 릴리 앤드 캄파니 | 페녹시에틸 시클릭 아민 유도체 및 ep4 수용체 조절제로서의 그의 활성 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| PE20191811A1 (es) | 2017-05-18 | 2019-12-26 | Idorsia Pharmaceuticals Ltd | Derivados de pirimidina como moduladores del receptor de pge2 |
| EP3625223B1 (en) | 2017-05-18 | 2021-08-11 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| WO2018210987A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Benzofurane and benzothiophene derivatives as pge2 receptor modulators |
| TWI768043B (zh) | 2017-05-18 | 2022-06-21 | 瑞士商愛杜西亞製藥有限公司 | N-取代吲哚衍生物 |
| KR102632028B1 (ko) | 2017-05-18 | 2024-01-31 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 페닐 유도체 |
| ES2995259T3 (en) * | 2019-01-22 | 2025-02-10 | Keythera Suzhou Pharmaceuticals Co Ltd | Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof |
| US20230390303A1 (en) | 2020-11-13 | 2023-12-07 | Ono Pharmaceutical Co., Ltd. | Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2500157C2 (de) | 1975-01-03 | 1983-09-15 | Hoechst Ag, 6230 Frankfurt | N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung |
| MXPA04005555A (es) * | 2002-03-18 | 2005-05-16 | Pfizer Prod Inc | Procedimientos de tratamiento con agonistas selectivos del receptor ep4. |
| KR100752891B1 (ko) * | 2003-01-10 | 2007-08-28 | 에프. 호프만-라 로슈 아게 | 프로스타글란딘 작용제로서 2-피페리돈 유도체 |
| WO2005021508A1 (en) * | 2003-09-03 | 2005-03-10 | Pfizer Inc. | Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists |
| US20050105732A1 (en) * | 2003-11-17 | 2005-05-19 | Hutchings George T. | Systems and methods for delivering pre-encrypted content to a subscriber terminal |
| AP2006003785A0 (en) * | 2004-05-04 | 2006-10-31 | Pfizer | Substituted methylaryl or heteroaryl amide compounds |
| BRPI0510598A (pt) * | 2004-05-04 | 2007-11-20 | Pfizer | compostos de amida de aril ou heteroaril substituìdos |
| US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
| US7968578B2 (en) | 2006-04-24 | 2011-06-28 | Merck Frosst Canada Ltd. | Indole amide derivatives as EP4 receptor antagonists |
| US7705035B2 (en) | 2006-06-12 | 2010-04-27 | Merck Frosst Canada Ltd. | Indoline amide derivatives as EP4 receptor ligands |
| WO2008092860A1 (en) * | 2007-01-30 | 2008-08-07 | Janssen Pharmaceutica N.V. | Bicyclic derivatives as ep4 agonists |
| WO2009139373A1 (ja) | 2008-05-14 | 2009-11-19 | アステラス製薬株式会社 | アミド化合物 |
| WO2010019796A1 (en) | 2008-08-14 | 2010-02-18 | Chemietek, Llc | Heterocyclic amide derivatives as ep4 receptor antagonists |
| BR112012020236A2 (pt) | 2010-02-22 | 2016-05-17 | Raqualia Pharma Inc | uso de um composto com atividade antagonística de ep4 ou um sal farmaceuticamente aceitável do mesmo, uso de um composto da fórmula (i), (ii), (iii), (iv), (va) ou (vb), ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica e método para o tratamento de doenças mediadas por il-23 em um sujeito animal, incluindo um sujeito mamífero |
| PE20131343A1 (es) * | 2010-09-21 | 2013-11-18 | Eisai Randd Man Co Ltd | Derivados de acido benzoico |
| EP2729445B1 (en) * | 2011-07-04 | 2015-10-21 | Rottapharm Biotech S.r.l. | Cyclic amine derivatives as ep4 receptor antagonists |
| US9120824B2 (en) * | 2011-07-04 | 2015-09-01 | Rottapharm Biotech S.R.L. | Cyclic amine derivatives as EP4 receptor agonists |
| JO3296B1 (ar) * | 2012-06-29 | 2018-09-16 | Lilly Co Eli | مركبات فينوكسي إيثيل بيبريدين |
-
2013
- 2013-06-13 JO JOP/2013/0177A patent/JO3296B1/ar active
- 2013-06-13 AR ARP130102076 patent/AR091429A1/es active IP Right Grant
- 2013-06-14 TW TW102121220A patent/TWI599561B/zh active
- 2013-06-20 PT PT137342481T patent/PT2867207T/pt unknown
- 2013-06-20 SI SI201330755T patent/SI2867207T1/sl unknown
- 2013-06-20 EA EA201492255A patent/EA024392B1/ru not_active IP Right Cessation
- 2013-06-20 MX MX2014015953A patent/MX345324B/es active IP Right Grant
- 2013-06-20 EP EP13734248.1A patent/EP2867207B1/en active Active
- 2013-06-20 MY MYPI2014703971A patent/MY173878A/en unknown
- 2013-06-20 PE PE2014002532A patent/PE20150182A1/es active IP Right Grant
- 2013-06-20 JP JP2015520304A patent/JP6127136B2/ja active Active
- 2013-06-20 HR HRP20171515TT patent/HRP20171515T1/hr unknown
- 2013-06-20 CN CN201380034168.8A patent/CN104411684B/zh active Active
- 2013-06-20 WO PCT/US2013/046684 patent/WO2014004229A1/en not_active Ceased
- 2013-06-20 KR KR1020147036137A patent/KR101653476B1/ko active Active
- 2013-06-20 MA MA37686A patent/MA37686B1/fr unknown
- 2013-06-20 DK DK13734248.1T patent/DK2867207T3/en active
- 2013-06-20 CA CA2875569A patent/CA2875569C/en active Active
- 2013-06-20 NZ NZ701933A patent/NZ701933A/en unknown
- 2013-06-20 BR BR112014031616-3A patent/BR112014031616B1/pt active IP Right Grant
- 2013-06-20 HU HUE13734248A patent/HUE034425T2/en unknown
- 2013-06-20 ME MEP-2017-223A patent/ME02840B/me unknown
- 2013-06-20 US US13/922,278 patent/US8962659B2/en active Active
- 2013-06-20 AP AP2014008164A patent/AP2014008164A0/xx unknown
- 2013-06-20 RS RS20171039A patent/RS56452B1/sr unknown
- 2013-06-20 PL PL13734248T patent/PL2867207T3/pl unknown
- 2013-06-20 UA UAA201413598A patent/UA114325C2/uk unknown
- 2013-06-20 SG SG11201408641UA patent/SG11201408641UA/en unknown
- 2013-06-20 ES ES13734248.1T patent/ES2644812T3/es active Active
- 2013-06-20 LT LTEP13734248.1T patent/LT2867207T/lt unknown
- 2013-06-20 AU AU2013280875A patent/AU2013280875B2/en active Active
-
2014
- 2014-11-24 ZA ZA2014/08632A patent/ZA201408632B/en unknown
- 2014-11-27 CO CO14261550A patent/CO7151507A2/es unknown
- 2014-11-28 TN TN2014000501A patent/TN2014000501A1/fr unknown
- 2014-12-03 CR CR20140553A patent/CR20140553A/es unknown
- 2014-12-11 IL IL236219A patent/IL236219A/en active IP Right Grant
- 2014-12-17 GT GT201400288A patent/GT201400288A/es unknown
- 2014-12-17 DO DO2014000287A patent/DOP2014000287A/es unknown
- 2014-12-26 CL CL2014003535A patent/CL2014003535A1/es unknown
- 2014-12-29 EC ECIEPI201433267A patent/ECSP14033267A/es unknown
-
2015
- 2015-01-05 PH PH12015500009A patent/PH12015500009B1/en unknown
- 2015-01-13 US US14/595,350 patent/US9402838B2/en active Active
-
2017
- 2017-09-15 CY CY20171100979T patent/CY1119425T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119425T1 (el) | Ενωσεις φαινοξυαιθυλο πιπεριδινης | |
| CY1122920T1 (el) | ΑΛΑΤΑ ΠΑΡΑΓΩΓΩΝ 2-ΑΜΙΝΟ-1-ΥΔΡΟΞΥΑΙΘΥΛ-8-ΥΔΡΟΞΥΚΙΝΟΛΙΝ-2(1Η)-ΟΝΗΣ ΠΟΥ ΕΧΟΥΝ ΔΡΑΣΕΙΣ ΤΟΣΟ ΑΝΤΑΓΩΝΙΣΤΗ ΜΟΥΣΚΑΡΙΝΙΚΩΝ ΥΠΟΔΟΧΕΩΝ ΟΣΟ ΚΑΙ ΑΓΩΝΙΣΤΗ β2 ΑΔΡΕΝΕΡΓΙΚΩΝ ΥΠΟΔΟΧΕΩΝ | |
| CY1121901T1 (el) | Ενωσεις τριαζολοπυριμιδινης και χρησεις αυτων | |
| CY1119585T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| CY1120480T1 (el) | Ενωσεις πυραζολοπυριμιδινης | |
| CY1122614T1 (el) | 11-υδροξυλ-6-υποκατεστημενα-παραγωγα χολικων οξεων και συζευγματα αμινοξεων αυτων ως ρυθμιστες υποδοχεων χ φαρνεσοειδων | |
| CY1121677T1 (el) | Ενωσεις διμεθυλοβενζοϊκου οξεος | |
| EA201691085A1 (ru) | Замещенные бензамиды и способы их применения | |
| CY1117105T1 (el) | Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao | |
| CR20150470A (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
| CY1117956T1 (el) | N3-αντικατεστημενα-n1-sulfonyl-5-fluoropyrimidinone παραγωγα | |
| EA201401054A1 (ru) | N-циклиламиды в качестве нематоцидов | |
| MX2017004200A (es) | Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos. | |
| EA201590534A1 (ru) | Новые бициклические производные | |
| CR20140464A (es) | Compuestos de heterociclilo | |
| CR20140548A (es) | Derivados de aril-sultamo como moduladores de rorc | |
| UY34602A (es) | ?Derivados de bencimidazolil- e imidazopiridinil-metilamina? | |
| EA201492214A1 (ru) | Ингибиторы вируса гепатита с | |
| CR20140084A (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
| CY1119583T1 (el) | Φαινοξυαιθυλο παραγωγα κυκλικης αμινης και η δραστικοτητα τους ως τροποποιητες του ερ4 υποδοχεα | |
| CY1117688T1 (el) | Ενωσεις τετραϋδροπυρρολοθειαζινης | |
| CY1119619T1 (el) | Παραγωγα πυριδιν-4-υλιου | |
| DOP2017000034A (es) | Compuestos de imidazopiridazina |